TY - JOUR
T1 - Level I PD-MCI using global cognitive tests and the risk for Parkinson's disease dementia
AU - Boel, Judith A.
AU - de Bie, Rob M. A.
AU - Schmand, Ben A.
AU - Dalrymple-Alford, John C.
AU - Marras, Connie
AU - Adler, Charles H.
AU - Goldman, Jennifer G.
AU - Tröster, Alexander I.
AU - Burn, David J.
AU - Litvan, Irene
AU - Geurtsen, Gert J.
AU - MDS Study Group Mild Cognitive Impairment in Parkinson's Disease
AU - Bernard, Bryan
AU - Stebbins, Glenn
AU - Filoteo, J. Vincent
AU - Weintraub, Daniel
AU - Caviness, John N.
AU - Belden, Christine
AU - Zabetian, Cyrus P.
AU - Cholerton, Brenna A.
AU - Huang, Xuemei
AU - Eslinger, Paul J.
AU - Leverenz, James B.
AU - Duff-Canning, Sarah
AU - Farrer, Matt
AU - Anderson, Tim J.
AU - Myall, Daniel J.
AU - Naismith, Sharon L.
AU - Lewis, Simon J. G.
AU - Halliday, Glenda M.
AU - Wu, Ruey Meei
AU - Williams-Gray, Caroline H.
AU - Breen, David P.
AU - Barker, Roger A.
AU - Yarnall, Alison J.
AU - Klein, Martin
AU - Mollenhauer, Brit
AU - Trenkwalder, Claudia
AU - Kulisevsky, Jaime
AU - Pagonabarraga, Javier
AU - Gasca-Salas, Carmen
AU - Rodriguez-Oroz, Maria C.
AU - Junque, Carme
AU - Segura, Barbara
AU - Barone, Paolo
AU - Santangelo, Gabriella
AU - Cammisuli, Davide M.
AU - Biundo, Roberta
AU - Antonini, Angelo
AU - Weis, Luca
AU - Pedersen, Kenn Freddy
AU - Alves, Guido
N1 - Copyright Amsterdam UMC 2022. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2022/5
Y1 - 2022/5
N2 - Background: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.
AB - Background: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.
KW - dementia
KW - diagnostic accuracy
KW - global cognitive tests
KW - mild cognitive impairment
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=85131576601&partnerID=8YFLogxK
U2 - 10.1002/mdc3.13451
DO - 10.1002/mdc3.13451
M3 - Article
C2 - 35582313
AN - SCOPUS:85131576601
SN - 2330-1619
VL - 9
SP - 479
EP - 483
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 4
ER -